Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Freeman

Showing results (11-20 of 191) with videos related to

Pageof 20
Sort By:
Trends in Endocrinology and Metabolism: TEM|March 22, 2008
Do the cholesterol-lowering properties of statins affect cancer risk?Keith R Solomon, Michael R Freeman
The Urologic Clinics of North America|July 30, 2011
The complex interplay between cholesterol and prostate malignancyKeith R Solomon, Michael R Freeman
Translational Cancer Research|February 4, 2022
ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancerMichael R Freeman, Mirja Rotinen, Sungyong You
Proteomics|February 26, 2008
Proteomic approaches to the analysis of multiprotein signaling complexesWei Yang, Hanno Steen, Michael R Freeman
Nature Reviews. Urology|May 13, 2018
Personalization of prostate cancer therapy through phosphoproteomicsWei Yang, Michael R Freeman, Natasha Kyprianou
Cancer Research|April 5, 2005
Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycinBekir Cinar, Arrigo De Benedetti, Michael R Freeman
Advances in Experimental Medicine and Biology|March 14, 2012
Caveolin-1 and prostate cancer progressionMichael R Freeman, Wei Yang, Dolores Di Vizio
Cancer Research|March 13, 2002
Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylationJayoung Kim, Rosalyn M Adam, Michael R Freeman
Cancer Research|September 17, 2005
Trafficking of nuclear heparin-binding epidermal growth factor-like growth factor into an epidermal growth factor receptor-dependent autocrine loop in response to oxidative stressJayoung Kim, Rosalyn M Adam, Michael R Freeman
Current Opinion in Pharmacology|July 25, 2012
Cholesterol and prostate cancerKristine Pelton, Michael R Freeman, Keith R Solomon
Pageof 20

Showing results (11-20 of 191) with videos related to

Sort By:
Pageof 20
Trends in Endocrinology and Metabolism: TEM|March 22, 2008
Do the cholesterol-lowering properties of statins affect cancer risk?Keith R Solomon, Michael R Freeman
The Urologic Clinics of North America|July 30, 2011
The complex interplay between cholesterol and prostate malignancyKeith R Solomon, Michael R Freeman
Translational Cancer Research|February 4, 2022
ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancerMichael R Freeman, Mirja Rotinen, Sungyong You
Proteomics|February 26, 2008
Proteomic approaches to the analysis of multiprotein signaling complexesWei Yang, Hanno Steen, Michael R Freeman
Nature Reviews. Urology|May 13, 2018
Personalization of prostate cancer therapy through phosphoproteomicsWei Yang, Michael R Freeman, Natasha Kyprianou
Cancer Research|April 5, 2005
Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycinBekir Cinar, Arrigo De Benedetti, Michael R Freeman
Advances in Experimental Medicine and Biology|March 14, 2012
Caveolin-1 and prostate cancer progressionMichael R Freeman, Wei Yang, Dolores Di Vizio
Cancer Research|March 13, 2002
Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylationJayoung Kim, Rosalyn M Adam, Michael R Freeman
Cancer Research|September 17, 2005
Trafficking of nuclear heparin-binding epidermal growth factor-like growth factor into an epidermal growth factor receptor-dependent autocrine loop in response to oxidative stressJayoung Kim, Rosalyn M Adam, Michael R Freeman
Current Opinion in Pharmacology|July 25, 2012
Cholesterol and prostate cancerKristine Pelton, Michael R Freeman, Keith R Solomon
Pageof 20